GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2025, recommended Final Dividend of 42 per equity share.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GlaxoSmithKline Pharmaceuticals reported strong FY25 results with standalone revenue from operations growing about 9.3% to Rs. 3,723 crore (vs Rs. 3,407 crore last year). Standalone profit after tax jumped roughly 57% to Rs. 919 crore (vs Rs. 585 crore), boosted by the absence of last year's one-time VRS (Voluntary Retirement Scheme) charge of Rs. 163 crore. The board recommended a final dividend of Rs. 42 per share (face value Rs. 10), up 31% from Rs. 32 in FY24, pending shareholder approval at the 100th AGM on June 27, 2025. Q4 standalone revenue grew about 6% to Rs. 966 crore with profit rising about 35% to Rs. 260 crore. The company also re-appointed Dr. Sunita Maheshwari as Independent Director for a second 3-year term and appointed Parikh & Associates as Secretarial Auditor for 5 years. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion.
Sharp profit growth, higher dividend, and clean audit opinion are positive for shareholders; the stock may see supportive sentiment, though much of the PAT jump reflects the non-repeat of last year's VRS cost rather than pure operational acceleration.